Pharmacovigilance and EU GDPR Compliance

Mar 6, 2018

Compliance with the new General Data Protection Regulation (GDPR), scheduled to become effective 25th May 2018, applies to all organizations that control or process personal data of European Union (EU) residents with or without a physical presence in the EU. As a pharmacovigilance solutions provider, ArisGlobal fully supports compliance with GDPR. Download this ArisGlobal position paper to understand:
  • GDPR and its major components related to enterprises
  • Its impact on pharmacovigilance-related activities – applicability, consent, data subject rights, PV data entry into the database, processing of PV data, data transfer to international organizations, data security, and the Data Protection Officer
  • ArisGlobal’s approach towards GDPR-related compliance – explained across multiple areas and providing our position for how companies can achieve compliance at the level of product, process and people
[contact-form-7 id="41" title="download the White Paper Default"]

About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn:
Follow @Aris_Global on Twitter:


Erika Thomas
+305-726-6601 |